Comparison of HIDs with ISDs in hematologic malignancies
| Study | Disease | No. (HID vs. ISD) | Protocol in HIDs | Survival and relapse |
|---|---|---|---|---|
| Wang, 2015 | AML in CR1 | 231 vs. 219 | G-CSF and ATG | 3-year DFS 74% vs. 78% (P = 0.34); relapse 15% vs. 15% (P = 0.98) |
| Wang, 2016 | ALL in CR1 | 103 vs. 83 | G-CSF and ATG | 3-year DFS 61% vs. 60%, (P = 0.91), relapse 18% vs. 24% (P = 0.30) |
| Wang, 2016 | MDS | 226 vs. 228 | G-CSF and ATG | 4-year RFS 58% (HLA 3/6) vs. 63% (HLA 4–5/6) vs. 71% (ISD) (P = 0.14) |
| Ghosh, 2016 | Lymphoma | 180 vs. 807 | PT-Cy based | 3-year PFS 48% vs. 48% (P = 0.96), disease progression (37% vs. 40%, P = 0.51) |
| Chang, 2017 | AML MRD+ | 56 vs. 20# | G-CSF and ATG | 4-year LFS 80% vs. 48% (P = 0.007), relapse 13% vs. 36% (P = 0.017) |
| Chang, 2020 | ALL MRD+ | 169 vs. 39 | G-CSF and ATG | 3-year LFS 65% vs. 43% (P = 0.023), relapse 23% vs. 47% (P = 0.006) |
| Yu, 2019 | High-risk AML | 83 vs. 106 | G-CSF and ATG | 3-year RFS 63% vs. 43% (P = 0.035), relapse 14% vs. 24% (P = 0.101) |
#Extracted from the prospective cohort. The bold values refer to “P <0.05” with significance.